TrialPharmacology research & perspectives2024

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.

John P Savaryn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.